Waivers For Shared REMS Will Depend On Impact To Generics, Docs, Patients

US FDA will take multiple factors into account when deciding whether single shared-system REMS requirement is necessary.

The US FDA will consider several factors when considering whether to grant a waiver of the single shared system Risk Evaluation and Mitigation Strategy requirement for a generic drug sponsor, including the impact a separate system could have on generic entry.

Draft guidance issued May 31 also outlines what ANDA sponsors should include in a waiver request, but FDA made clear...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Drug Safety

More from Pink Sheet